Mizuho Maintains Outperform on Enliven Therapeutics, Raises Price Target to $45

Mizuho analyst Salim Syed has maintained an 'Outperform' rating on Enliven Therapeutics (NASDAQ: ELVN) and increased the price target from $41 to $45. This adjustment reflects a positive outlook on the company's performance.